← Leaderboards
Roberto Machado
University Of Illinois At Chicago
$965,282
Attributed
$965,282
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $323.4K · FY2017–19$500K$375K$250K$125K$0
'17
'18
'19
Funding mix
By agency
NIH$965,282 · 1
By mechanism
N01$965,282 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- You-Yang Zhao$24,398,532
- Jan K. Kitajewski$18,741,116
- Peter Buttrick$13,327,562
- John Varga$15,528,672
- Richard D Minshall$14,002,730
Others in their field
Other Emerging Leaders on “Adverse Effects”
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Kristin Aillon · Midwest Research Institute$23,644,534
- Abraham Aizer Brody · New York University School Of Medicine$21,887,280
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$21,828,548
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
Research focus
Adverse EffectsAortic AneurysmAreaClinical EffectCoronary ArteriosclerosisDesignDissectionInhibitor/AntagonistInterestIntracranial ArteryLymphatic DiseasesLymphatic SystemNicotinamide PhosphoribosyltransferasePeripheral Arterial DiseasePharmaceutical PreparationsProduct DevelopmentProgramsPulmonary Arterial HypertensionPulmonary HypertensionPulmonary Vascular DisorderTargeted AgentThrombosisVascular DiseasesVenous
Grant awards (3)
IGF::OT::IGF - DEVELOPMENT OF NAMPT INHIBITORS TO TREAT PULMONARY ARTERIAL HYPERTENSION$323,412
N01 · FY2019 · HL · contact PI
DEVELOPMENT OF NAMPT INHIBITORS TO TREAT PULMONARY ARTERIAL HYPERTENSION, VITA 2$323,436
N01 · FY2018 · HL · contact PI
IGF::OT::IGF - DEVELOPMENT OF NAMPT INHIBITORS TO TREAT PULMONARY ARTERIAL HYPERTENSION$318,434
N01 · FY2017 · HL · contact PI